#RWE is increasingly recognized for its value and impact, bridging gaps in knowledge alongside evidence from #ClinicalTrials. Explore further below 👇 Thank you A-Barzi & Pedro Uson Junior, MD for your contributions!

NTRK gene fusion in thyroid cancer: Unlock the potential of precision medicine 👉 buff.ly/4aAMKZU Delve into the latest on genomic testing and targeted therapy for patients with NTRK gene fusion-positive thyroid cancer #Endocrinology #Oncology #MedEd

Bayer Oncology will be attending #ASCO24 🙌 Learn more about Bayer’s exciting pipeline and mission in precision oncology by visiting our medical booth (#17078). More information can also be found on the Oncology Pipeline website 👇 #CancerResearch #PrecisionOncology ASCO

New data from the ARAMIS trial will be presented at #ASCO24. Learn more about the association between PSA level and risk of radiological progression in patients with #nmCRPC from this follow-up analysis 👇 Abstract 5022, Poster 318

A new post hoc analysis of the ARASENS trial evaluated post-progression survival in patients with #mHSPC. Visit Marc-Oliver Grimm at Poster 489 to learn more 👇 Abstract 5083, Poster 489 #ASCO24

#ASCO24 update 🔔 In this modular phase 1 trial, the combination of fractionated chemotherapy with a radiopharmaceutical was evaluated in patients with #mCRPC. Check out the abstract to learn more 👇 Abstract 5049, Poster 455

A phase 1b/2 trial investigated an oral multi-kinase inhibitor with an anti–PD-1 antibody and #chemotherapy as 1L therapy in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma. Learn more at #ASCO24 👇 Abstract 4052, Poster 32 #GICancer

New data are available on outcomes in patients with #TRKFusion cancer at #ASCO24. Learn more about the VICTORIA study, which compared results from a TRK inhibitor with real-world data from non-TRK inhibitors. Abstract 3105, Poster 250 #TRKFusionCancer ASCO

Hear Anthony El-Khoueiry discuss results from an open-label phase 2 study in patients with advanced #HCC at #ASCO24🔬 In this study, patients who were previously treated with ICIs received an oral multi-kinase inhibitor plus an anti–PD-1 monoclonal antibody. Learn more 👇 ASCO

#ASCO24: Learn about the safety and anti-tumor activity of an oral, reversible tyrosine kinase inhibitor (TKI) in patients with #HER2-mutant #NSCLC 🫁 Abstract LBA8598, Poster 462 #LungCancer ASCO

🎯 How can molecular profiling guide cancer therapy? Join our experts to learn how to best utilize molecular testing in clinical practice. ➡️ ms.spr.ly/6014lKY8Q #precisionmedicine #OncTwitter #oncx

The use of liquid biopsy as a diagnostic method is a pivotal advancement in molecular testing Join Umberto Malapelle as he discusses the role of liquid biopsy in precision oncology, focusing on NSCLC, breast cancer, and CRC Find the full #MedEd video 👉🎬ow.ly/JSn450SAbmz

#News from our Phase III trial in patients with #mHSPC 📢 The trial met its primary endpoint. #ProstateCancer

Are you aware of currently approved tumor-agnostic drugs? Come join the experts to learn more about them and better understand their impact and the evolving treatment landscape. Come have a listen! 🎧 medscape.org/viewarticle/10…

Dr. Vivek Subbiah, MD discusses key advances in precision oncology in the first of the expert series from the clinical advances in PRecision Oncology: Medical Innovations and Scientific Exchange (PROMISE). ms.spr.ly/6017leX6P

Are you attending #WCLC24? Join the conversation on diversity and inclusion at this Bayer-supported IASLC’s symposium. We will explore challenges, opportunities and efforts to address inequalities in thoracic oncology. Learn more 👇 #InclusionMatters